Aztreonam

Monobactam Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Aztreonam is an ofp drug in the Monobactam Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1986. DrugCentral lists 11 molecular targets, including sugE, bla LAT-2 and Beta-lactamase. Recorded indications include Aerobic Gram-Negative Bacteremia, Bacterial Exacerbation of Acute Bronchitis, Bacterial infection due to Klebsiella pneumoniae and Bacterial infection due to Serratia.

• Approval status: ofp (first approved 1986 by the FDA).
• Drug class: Monobactam Antibacterial.
• Molecular targets: sugE, bla LAT-2, Beta-lactamase and blaACC-4 (11 listed in DrugCentral).
• Indications: Aerobic Gram-Negative Bacteremia, Bacterial Exacerbation of Acute Bronchitis, Bacterial infection due to Klebsiella pneumoniae, Bacterial infection due to Serratia and Bacterial peritonitis and others.
• ATC code: J01DF01 (Monobactams).
• Molecular formula: C13H17N5O8S2; molecular weight 435.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (58)

• Aerobic Gram-Negative Bacteremia
• Bacterial Exacerbation of Acute Bronchitis
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial infection due to Serratia
• Bacterial peritonitis
• Bacterial urinary infection
• Citrobacter Peritonitis
• Citrobacter Urinary Tract Infection
• E. Coli Bronchitis
• E. Coli Endometritis
• E. Coli Pelvic Inflammatory Disease
• E. Coli Peritonitis
• Endometritis
• Enterobacter Cloacae Bronchitis
• Enterobacter Endometritis
• Enterobacter Pelvic Inflammatory Disease
• Enterobacter Pneumonia
• Escherichia coli urinary tract infection
• Female genital tract infection
• Gram-Negative Aerobic Bacillary Pneumonia
• Haemophilus Influenzae Bronchitis
• Haemophilus influenzae pneumonia
• Infection due to Enterobacteriaceae
• Infection due to Escherichia coli
• Infection due to Pseudomonas aeruginosa
• Infection of skin AND/OR subcutaneous tissue
• Infectious disease of abdomen
• Inflammatory Disease of Female Pelvic Organs
• Klebsiella cystitis
• Klebsiella Endometritis
• + 28 more

Contraindications (4)

• Bronchospasm
• Disease of liver
• Kidney disease
• Pseudomembranous enterocolitis

Mechanism & targets

• Established pharmacologic class: Monobactam Antibacterial

Molecular targets (11)

Target	Gene	Action	Activity
Efflux transporter; SugE	sugE	unknown	IC50 8.22
Beta-lactamase	bla LAT-2	unknown	IC50 8.22
Beta-lactamase	—	unknown	Ki 8.15
Beta-lactamase	blaACC-4	unknown	IC50 7.49
AmpC	ampC	unknown	IC50 7.22
Peptidoglycan synthase FtsI	ftsI	inhibitor	IC50 5.74
Beta-lactamase	blaPER-2	unknown	Ki 5.70
Beta-lactamase	ampC	unknown	Ki 5.52
Penicillin-binding protein 1A	mrcA	unknown	IC50 5.48
Penicillin-binding protein 1A	mrcA	inhibitor	IC50 5.32
Penicillin-binding protein 1B	mrcB	inhibitor	IC50 4.32

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2009-09-21	EMA	—	GILEAD SCIENCES IRELAND UC
1986-12-31	FDA	—	BRISTOL MYERS SQUIBB	Yes

ATC classification

ATC code	Therapeutic hierarchy
J01DF01	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Monobactams
J01DF51	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Monobactams

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Infective pulmonary exacerbation of cystic fibrosis	2848.8
Cystic fibrosis	812.5
Lung transplant	599.6
Death	505.4
Eosinophilia	357.6
Pulmonary function test decreased	328.6
Hospitalisation	322.3
Bacterial disease carrier	288.5
Haemoptysis	281.8
Bronchial secretion retention	248.0
Superinfection	247.4
Pseudomonas infection	234.1

Chemical structure

• Molecular formula: C₁₃H₁₇N₅O₈S₂
• Molecular weight: 435.43 g/mol
• CAS number: 78110-38-0
• InChIKey: WZPBZJONDBGPKJ-VEHQQRBSSA-N
• PubChem CID: 5742832

C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Aztreonam used for?

DrugCentral lists the following indications for Aztreonam: Aerobic Gram-Negative Bacteremia, Bacterial Exacerbation of Acute Bronchitis, Bacterial infection due to Klebsiella pneumoniae, Bacterial infection due to Serratia, Bacterial peritonitis, Bacterial urinary infection, Citrobacter Peritonitis and Citrobacter Urinary Tract Infection and others.

How does Aztreonam work?

Its molecular targets in DrugCentral include sugE, bla LAT-2, Beta-lactamase and blaACC-4.

When was Aztreonam first approved?

Aztreonam was first approved by the FDA in 1986.

What drug class does Aztreonam belong to?

Aztreonam is in the Monobactam Antibacterial class.

What is the chemical formula of Aztreonam?

Aztreonam has the molecular formula C13H17N5O8S2 and a molecular weight of 435.43 g/mol.

Sources

• DrugCentral drug card 279 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL158 — compound record and bioactivity
• PubChem CID 5742832 — chemical identifiers
• DrugBank DB00355 — drug record
• FDA UNII G2B4VE5GH8 — substance identity
• DailyMed: FDA labels for Aztreonam — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.